Trial Profile
A prospective, non-randomised, non-controlled, open label, multicentre, phase II study: PTK 787/ZK222584 [vatalanib] in patients with advanced neuroendocrine tumours. (UHL 9867 Schering-Charite-NET)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 17 Feb 2006 New trial record.